raguneprocel (CT1-DAP001) / Sumitomo Pharma - LARVOL DELTA

Announcement of a Subsidiary’s Submission of the Application of Manufacturing and Marketing Authorization for an iPS Cell-Derived Product for Parkinson’s Disease in Japan (Sumitomo Chemical Press Release) - "Sumitomo Pharma Co., Ltd...and RACTHERA Co., Ltd...hereby announce that...they have submitted an application of manufacturing and marketing authorization for allogeneic iPS cell-derived dopaminergic neural progenitor cells (INN: 'raguneprocel', 'the Product') for indication of the improvement of motor functions during the off-time period of patients with advanced Parkinson’s disease. The applicant for the authorization is Sumitomo Pharma. This submission was based on the data from the investigator-initiated trial conducted by Kyoto University Hospital, and its results were published in the journal Nature in April 2025...The Product has been designated by the Ministry of Health, Labour and Welfare as a product for priority review under the SAKIGAKE Designation System."

Japan filing • Priority review • Parkinson's Disease

A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects with Parkinson's Disease (clinicaltrials.gov) - P1 | N=23 | Recruiting | Sponsor: Sumitomo Pharma America, Inc.

New P1 trial • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease

Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II) (clinicaltrials.gov) - P1 | N=7 | Recruiting | Sponsor: University of California, San Diego

New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease • Transplantation